Indian Heart Journal

Permanent URI for this collection

https://imsear.searo.who.int/handle/123456789/1363

Browse

Browsing Indian Heart Journal by Author "Abdulkader, Rizwan Suliankatchi"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Comparison of hybrid coronary revascularization versus conventional Coronary Artery Bypass surgery in patients with multi-vessel coronary artery disease in a real-world setting: In-hospital outcomes and medium-term follow-up: COHOS study
    (Elsevier, 2025-04) Kaliyamoorthy, Dhamodaran; Yusuf, Meeranghani Mohamed; Ramalingam, Vadivelu; Kasha, Abhishek; Kathiresan, Manickam; Abdulkader, Rizwan Suliankatchi; Kathiresan, Jeyashree; Kumar, Aishwarya Mahesh; Grace, Elsa; Choudhury, Anirban
    Objectives: The aim of this observational study was to evaluate the in-hospital and medium-term outcomes of hybrid coronary revascularization (HCR) in the real-world setting compared to conventional coronary artery bypass grafting (CABG). Methods: All patients with multi-vessel coronary artery disease (MV-CAD) who underwent conventional CABG and HCR in our institution between January 2018 to January 2021 were evaluated in terms of length of intensive care unit (ICU), in-hospital stay, repeat revascularization rates, bleeding, stroke, and in-hospital mortality. Clinical outcomes (mortality and major adverse cardiac and cerebrovascular events [MACCE]) were assessed at average follow up of 3.6 years. Results: Pre-procedural characteristics were balanced between the groups after propensity score matching. There was no significant difference in MACCE [Odds ratio: 0.57; 95 % CI: 0.05 to 1.52; p = 0.66], in-hospital mortality [n = 2 (1.9 %) vs n = 0; p = 0.80], post procedure stroke [n = 2 (1.9 %) vs n = 2 (3.7 %); p = 0.86], post- procedural myocardial infarction requiring repeat revascularization [n = 2 (1.9 %) versus n = 1 (1.9 %); p = 1] during the in-hospital stay of the patients in the CABG vs HCR groups respectively. HCR was associated with significantly lower requirement for blood transfusions, bleeding risk, in-hospital stay, and intensive care unit stay. Analysis of the outcomes after 3.6 years revealed no significant difference in MACCE [Odds ratio: 1.40; 95 % CI: 0.46 to 4.30; p = 0.55], and post discharge mortality [n = 0 vs n = 0; p = 1]. Both groups had similar rates of post-procedural myocardial infarction requiring repeat revascularization [n = 0 vs n = 4 (7.4 %); p = 0.278], and rate of re-intervention [n = 0 vs n = 3 (5.6 %); p = 0.41]. Conclusion: HCR may be considered as a safe and feasible alternative to conventional CABG in selected in- dividuals with MV-CAD.
  • No Thumbnail Available
    Item
    Safety and efficacy of protamine after transcatheter aortic valve replacement
    (Elsevier, 2024-10) Kumaraguruparan, Lakshmi Durga; Anandaram, Asuwin; Sambandam, Kamalakkannan G.; Chidambaram, Yogapriya; Kidambi, Bharath Raj; Karthikeyan, Gautam Ganesan; Kasi, Madhesh; Abdulkader, Rizwan Suliankatchi; Ramesh, Sankaran; Ramalingam, Vadivelu; Rajendran, Ravindran; Senguttuvan, Nagendra Boopathy
    Transfemoral Trans-catheter Aortic Valve Replacement (TF-TAVR) is a safe alternative to surgical aortic valve replacement (SAVR). Protamine is used to reverse heparin and reduce post-TAVR bleeding, but concerns about risks like valve thrombosis and stroke remain. This systematic review and meta-analysis, following PRISMA guidelines, found no statistically significant difference in major bleeding complications between the protamine and control groups [(3.0 % vs. 14.4 %); RR: 0.56; P = 0.16]. No differences were noted in life-threatening bleeding, blood transfusions, 30-day mortality, or stroke. Protamine appears safe post-TAVR without increasing stroke risk, but its effectiveness in reducing bleeding needs further investigation through a multi- centric randomized study.